Entrada Therapeutics Inc

NASDAQ:TRDAUnited States

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.

Contact Information

Headquarters

One Design Center Place, Suite 17-500BOSTON, MA, United States 02210

Phone

857-305-1825

Fax

302-655-5049

Executives

Independent Chairman of the Board

Kush Parmar

President, Chief Operating Officer

Nathan Dowden

Chief Executive Officer, Director

Dipal Doshi

Chief Financial Officer, Treasurer

Kory Wentworth

Chief Scientific Officer

Natarajan Sethuraman